Adobe stock photos - Matthew US Pharma PricesEli Lilly and Novo Nordisk slash obesity drug pricesEli Lilly and Novo Nordisk cut US obesity drug prices under Trump’s MFN plan, offering Zepbound, Wegovy and others via Medicare, Medicaid and LillyDirect. more ➔
Parse BiosciencesAI/single cell analysisQIAGEN acquires Parse Biosciences Inc for US$225mBiotech leader QIAGEN NV announced the acquisition of Parse Biosciences for US$225M upfront, plus up to US$55M in milestone payments, expected to close by the end of 2025. more ➔
Boehringer IngelheimPartnershipBoehringer Ingelheim in US$570m deal with CDR-LifeBoehringer Ingelheim has licenced global rights for CDR111, an antibody-based trispecific M-gager to treat autoimmune diseases from CDR-Life, Inc. CDR111 is an antibody-based T-cell engager designed … more ➔
adobe stock photos - MikeCS Images Retinal diseasesAAVantgarde secures $141m Series B fundingAAVantgarde Bio has closed a $141M (€122M) Series B financing round led by Schroders Capital, Atlas Venture, and Forbion. New investors included Amgen Ventures, Athos Capital, CDP Venture Capital, … more ➔
Adobe stock photos - https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/M&ANovo and Pfizer in Metsera takeover battleDanish Novo Nordisk A/S has made an unexpected takeover bid for US biotech Metsera, Inc. This challenges the already agreed acquisition by Pfizer Inc. Novo offers US$6.5bn in cash, plus up to US$2.5bn … more ➔
NATODefenceNATO elevates biotech to defence priorityThe NATO is clearly priorising biotech to a defence priority with an annual budget of potentially up to €500m for biotech start-ups starting from 2026. At the opening of the first ever NATO Biotechnology … more ➔
GSKLicence dealGSK licences siRNA COPD drug in US$745m biobucks dealBritish GlaxoSmithKline plc (GSK) has entered a US$745m licensing agreement with Empirico Inc for EMP-012, a first-in-class siRNA candidate for COPD. EMP-012 targets the underserved non-type 2 inflammation … more ➔
adobe stock photos - Michael Derrer Fuchs M&ANovartis acquires Avidity Biosciences for US$12bnIn a major bet on RNA medicine, Swiss Novartis AG announced to buy Avidity Biosciences Inc for US$12bn. Avidity’s Oligonucleotide Conjugate (AOC) platform allows Transferin receptor-targeted RNA delivery … more ➔
Adobe stock photo - tippapatt FinancingGHO Capital expands healthcare reach with €2.5bn Fund IV closeGHO Capital has closed its fourth fund, GHO Capital IV LP, raising over €2.5bn (~US$2.9bn) to invest in global healthcare. The fund brings the firm’s total assets under management to around €9bn, … more ➔
adobe stock photos - Jiraporn FinancingHemab Therapeutics bags US$157m in Series C financingHemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round led by Sofinnova Partners to accelarate and expand its pipeline in bleeding disorders and thrombosis treatment … more ➔
Adobe stock photos - Matthew 
Parse Biosciences
Boehringer Ingelheim
adobe stock photos - MikeCS Images 
Adobe stock photos - https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/
NATO
GSK
adobe stock photos - Michael Derrer Fuchs 
Adobe stock photo - tippapatt 
adobe stock photos - Jiraporn